This dialysis-fluid supply system, which mixes a diluent and at least two drugs to generate a dialysis fluid, and outputs said dialysis fluid, is provided with: a mixing tank which mixes the drugs and the diluent to generate the dialysis fluid; a storage tank which stores and outputs the dialysis fluid generated by the mixing tank; a transport mechanism for transporting, to the storage tank, the dialysis fluid generated by the mixing tank; an output mechanism for outputting, to a dialysis device, the dialysis fluid stored in the storage tank; and a control unit for controlling the driving of the transport mechanism and the output mechanism.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Methods for the generation of electrochemical plasma activated aqueous chemotherapeutics (EPAAC) solutions are described. These solutions have been found to selectively reduce the proliferation of human pancreatic cancer cells, with no toxic effects for healthy cells.

The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

The disclosure herein relates to therapeutically active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation. Specifically, the disclosure relates to strontium either in salt or complex form and at least one molecule selected from chlorogenic acid, agmatine, kynurenic acid, nobiletin, or tangeretin, which can be topically applied. Optionally, the formulations include enhancement agents such as vitamins, soothing agents, moisturizers, polymers and the like.

The disclosure herein relates to therapeutically active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation. Specifically, the disclosure relates to strontium either in salt or complex form and at least one molecule selected from chlorogenic acid, agmatine, kynurenic acid, nobiletin, or tangeretin, which can be topically applied. Optionally, the formulations include enhancement agents such as vitamins, soothing agents, moisturizers, polymers and the like.

The invention relates to, for example, a respirable dry powder that contains respirable dry particles that contains a tiotropium salt, one or more amino acids, sodium chloride, and optionally one or more additional therapeutic agents, where the tiotropium salt is about 0.01% to about 0.5%, the one or more amino acids is about 5% to about 40%, the sodium chloride is about 50% to about 90%, and the optional one or more additional therapeutic agents are up to about 30%, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein the majority of the one or more amino acids are present in a crystalline state.

The invention relates to, for example, a respirable dry powder that contains respirable dry particles that contains a tiotropium salt, one or more amino acids, sodium chloride, and optionally one or more additional therapeutic agents, where the tiotropium salt is about 0.01% to about 0.5%, the one or more amino acids is about 5% to about 40%, the sodium chloride is about 50% to about 90%, and the optional one or more additional therapeutic agents are up to about 30%, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein the majority of the one or more amino acids are present in a crystalline state.